EDITORIAL

This is an open access article which permits unrestricted non-commercial use, provided it is properly cited. ISSN (0): 2349-5332 CODEN: IRJPHY





EDITORIAL

NEW DRUG DISCOVERY

The significance of new drug discovery lies in its potential to save lives, improve quality of life, and reduce healthcare costs over time. Every breakthrough in this field brings us closer to curing diseases that were once thought incurable, treating conditions more effectively, and minimizing side effects. It is not just about creating better medications; it's about redefining what is medically possible, pushing the boundaries of science and technology to foster a healthier world.

However, the path to discovering new drugs is fraught with challenges. The process from initial discovery to market can take over a decade and cost billions of dollars, with a high rate of failure at various stages. For every successful drug, thousands of potential candidates fail during preclinical testing or clinical trials. The financial risk is enormous, and the scientific hurdles are steep, requiring a deep understanding of diseases at a molecular level, innovative research methodologies, and robust regulatory frameworks to ensure safety and efficacy.

Looking forward, the future of new drug discovery is bright, driven by advances in genomics, artificial intelligence (AI), and personalized medicine. Technologies like CRISPR gene editing and AI-powered drug design are revolutionizing how we identify and develop new drugs, making the process faster, more efficient, and increasingly targeted to individual patient needs. The integration of big data analytics allows for the identification of novel drug targets and the prediction of drug efficacy and side effects, streamlining the development process.

Piuse Pallavi Pandey

Assistant Manager, Hetero Biopharma Ltd. E-Mail: piusedr@gmail.com Indian Research Journal of Pharmacy and Science; 38(2024)2967; Journal Home Page: https://www.irjps.in